Summary
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, otorhinolaryngology, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, and sports and aging care supplements. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
History
The company was established in 1916 to produce explosives for the construction sector. The firm then diversified into chemical dyes and pharmaceuticals in the interwar period.By 1950, Nippon Kayaku had established itself as the ninth leading pharmaceutical firm in Japan. The launch of its anticancer drug, bleomycin, strengthened the firm's pharmaceutical business.
Mission
Nippon Shinyaku's mission is to make a contribution to society through the production and distribution of innovative, effective and safe medicines, while always considering the convenience of patients and healthcare providers.
Vision
Nippon Shinyaku's vision is to be a global leader in driving innovation in the health care industry by developing cutting-edge medicines, advanced technology and novel services.
Key Team
Koji Honma (Gen. Mang. of Personnel Dept.)
Hirokata Harada (Head of Medical Affairs Division & Corp. Officer)
Mr. Takanori Edamitsu (GM of Bus. Management & Sustainability and Director)
Mr. Kazuchika Takagaki (GM of R&D Division & Director)
Mr. Hitoshi Ishizawa (GM of Functional Food Division & Director)
Masaya Toda (Head of Licensing & Alliance Division and Corp. Officer)
Masafumi Taira (Corp. Officer & Head of Clinical Devel. Div.)
Recognition and Awards
Nippon Shinyaku has won numerous industry awards over the years, including the prestigious Japan Pharmaceutical Association Award, the Society of Pharmaceutical Sciences Award and the Quality of Life Grand Award.
References
Japan 
